Karl Keegan

Biotechnology Valuation

An Introductory Guide

• Gebundenes Buch

Produktbeschreibung

Biotechnology valuation

An Introductory Guide

Karl Keegan

Written by experienced financial analyst, Karl Keegan, Biotechnology Valuation: An Introductory Guide is a hands-on guide to the valuation of biotechnology companies both from a private and public market perspective for industry professionals, investors and students.

Focused on product based biotechnology investments and drawing on the author's extensive experience the book begins by valuing healthcare focussed biotechnology companies which are trying to develop new therapeutics using traditional valuation metrics for those readers unfamiliar with finance. The book then takes these principles and applies them to the unique aspects of biotechnology valuation. A background guide to the intricacies of drug development is provided including descriptions of the different clinical phases, relevant regulatory pathways and the attributes that contribute to make a successful drug. The financial analysis and the technical assessment are then combined to take the reader through multiple investment techniques that can applied for biotechnology company valuation including product NPVs, DCF valuation and real options analysis. Real world examples are used throughout the book to illuminate some of the softer aspects of valuation. The book also reviews the different methodologies used for valuing private companies in order to reduce risk and increase returns.

By highlighting some of the most common pitfalls of biotechnology valuation and providing a toolkit to establishing the value of a biotechnology company, Biotechnology Valuation: An Introductory Guide will enable the reader to develop a consistent approach and have a useful toolkit to tackle the valuation of a biotechnology company or individual drug, with confidence.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Wiley Finance Series
• Verlag: Wiley & Sons
• Artikelnr. des Verlages: 14551178000
• 1. Auflage
• Seitenzahl: 224
• Erscheinungstermin: 14. Januar 2009
• Englisch
• Abmessung: 250mm x 175mm x 17mm
• Gewicht: 556g
• ISBN-13: 9780470511787
• ISBN-10: 0470511788
• Artikelnr.: 24710334

Autorenporträt

KARL KEEGAN is currently a managing director and global head of life sciences equity research at CanaccordAdams, a global investment bank focussing on small to mid cap companies. Karl has been a financial analyst covering the biotechnology sector for over eleven years and has previously worked at Dresdner Kleinwort Benson, UBS and Banc of America. Karl and his team have been consistently highly ranked in institutional surveys throughout his career. Prior to embarking on his finance career, Karl completed postdoctoral assignments in the US and UK and worked in the pharmaceutical industry both as a bench scientist and in strategic planning. Dr. Keegan holds a BSc in Pharmacology from University College Dublin, Ireland, MPhil and PhD degrees in Pharmacology from University of Cambridge, UK and MSc in Finance from London Business School, UK. A native of Dublin, Ireland, he now lives in Kent, UK.

Inhaltsangabe

Acknowledgements xi
1 Introduction 1
Biotechnology Background 5
2 Traditional Valuation Methods 11
The Value of a Company 11
Accounts - Providing the Data for Valuation Analysis 12
The Income Statement 13
Balance Sheet 17
Cash Flow Statement 20
Income Statement Multiples 22
Balance Sheet Multiples 26
Summary 27
Discounted Cash Flow Analysis 27
Net Present Value 27
Constructing the DCF 28
Projecting the Cash Flow Stream 29
Choosing a Discount Rate 30
Other Thoughts 37
3 The Drug Development Process 39
The Drug Development Process 40
Drug Discovery and Research 44
Pre-Clinical Development 44
Clinical Trials 48
What Investors Should Look For When Analysing Clinical Trials 56
Conclusion 59
The Regulatory Process 59
Regulation in the US 60
Regulation in Europe 63
The Label 64
Timelines for Approval 65
Post Approval 65
Investment Lessons 66
Case Study # 1 66
4 Biotechnology Company Valuation 69
Data Collation 71
NPV of the Pipeline 75
Calculations 80
Sensitivity Analyses 86
DCF of Whole Company 92
EBIT DCF of Products 97
Comparables Valuation 99
NPVs are Additive 101
Using all the Tools Available to Reach a Valuation Conclusion 101
Market Models 104
Conclusion 105
Appendix 1 106
Example 1 106
Example 2 108
Example 3 108
Appendix 2 116
Biosimilar Update 116
5 Decision Trees and Real Options 119
Decision Trees 120
Discount Rate 124
Deriving Scenarios 125
Conclusion 125
Decision Tree Example 126
Real Options 126
Valuing Options 129
Estimation of the Input Variables 138
Conclusions 139
6 Biotechnology Investing 141
Types of Healthcare Investment 141
Biotechnology Sector Evolution 143
Biotechnology Investment Cycles 145
Biotechnology Business Models 152
Focus on People 154
Cash 155
Product Pipeline 155
Commercial Risks 156
Newsflow 158
Lessons from Biotech Investing 160
7 Early-stage Valuation 161
Private Valuation 162
Discounted Cash Flow Method 166
Comparable Valuation 168
Venture Capital Method 170
Discount Rates 173
Conclusion 173
Glossary 175
References 189
Index 193